Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPTNNASDAQ:ORICNASDAQ:TRMLNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPTNOptiNose$9.60$9.48$4.82▼$19.50$97.22M-0.8865,161 shsN/AORICOric Pharmaceuticals$10.00+7.4%$6.71$3.90▼$14.67$793.44M1.49784,830 shs814,185 shsTRMLTourmaline Bio$17.02+2.3%$16.79$11.56▼$29.79$427.41M2.05273,864 shs193,476 shsVERVVerve Therapeutics$11.11+0.5%$5.63$2.86▼$11.41$985.92M1.672.38 million shs5.51 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPTNOptiNose0.00%0.00%0.00%+4.69%-41.28%ORICOric Pharmaceuticals+7.41%+6.27%+57.48%+48.15%+38.31%TRMLTourmaline Bio+2.28%-10.28%+11.10%-0.58%+11.24%VERVVerve Therapeutics+0.45%+77.19%+154.82%+90.24%+110.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPTNOptiNose0.7905 of 5 stars1.00.00.04.20.01.70.6ORICOric Pharmaceuticals4.1443 of 5 stars3.50.00.04.33.33.30.6TRMLTourmaline Bio2.0142 of 5 stars3.53.00.00.00.62.50.0VERVVerve Therapeutics2.9631 of 5 stars4.21.00.00.02.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPTNOptiNose 2.00Hold$9.00-6.25% DownsideORICOric Pharmaceuticals 3.00Buy$19.1791.67% UpsideTRMLTourmaline Bio 3.00Buy$49.33189.86% UpsideVERVVerve Therapeutics 2.38Hold$14.7532.76% UpsideCurrent Analyst Ratings BreakdownLatest OPTN, VERV, ORIC, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.006/18/2025VERVVerve TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.006/18/2025VERVVerve TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.006/18/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.506/17/2025VERVVerve TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform6/17/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$39.00 ➝ $13.005/29/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/6/2025ORICOric PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICOric PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/AVERVVerve Therapeutics$32.33M30.63N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%8/14/2025 (Estimated)Latest OPTN, VERV, ORIC, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million5/5/2025Q1 2025ORICOric Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A3/26/2025Q4 2024OPTNOptiNose-$0.70-$0.03+$0.67-$0.03$21.02 million$21.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPTNOptiNoseN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPTNOptiNoseN/A0.790.72ORICOric PharmaceuticalsN/A12.0012.00TRMLTourmaline BioN/A33.8733.87VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPTNOptiNose85.60%ORICOric Pharmaceuticals95.05%TRMLTourmaline Bio91.89%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipOPTNOptiNose2.30%ORICOric Pharmaceuticals6.82%TRMLTourmaline Bio13.00%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableORICOric Pharmaceuticals8085.22 million80.49 millionOptionableTRMLTourmaline Bio4425.68 million22.35 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableOPTN, VERV, ORIC, and TRML HeadlinesRecent News About These CompaniesLilly To Acquire Verve For One-Time Cardiovascular TreatmentsJune 23 at 2:58 AM | insidermonkey.comResearch Analysts Offer Predictions for VERV Q2 EarningsJune 21 at 1:17 AM | americanbankingnews.comWhy Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This WeekJune 20, 2025 | fool.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)June 20, 2025 | globenewswire.comLifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to HoldJune 20, 2025 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC WainwrightJune 20, 2025 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial GroupJune 20, 2025 | americanbankingnews.comQ2 Earnings Forecast for VERV Issued By Lifesci CapitalJune 19, 2025 | marketbeat.comEli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart DrugJune 19, 2025 | insidenova.comVerve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3BJune 19, 2025 | msn.comVerve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William BlairJune 19, 2025 | americanbankingnews.comVERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERVJune 18, 2025 | businesswire.comGene-Editing Stocks Gain on LLY-VERV Deal AnnouncementJune 18, 2025 | zacks.comVerve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC WainwrightJune 18, 2025 | marketbeat.comLifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)June 18, 2025 | marketbeat.comVerve Therapeutics' (VERV) "Hold" Rating Reiterated at Jefferies Financial GroupJune 18, 2025 | marketbeat.comLock In The 81.5% Run - Initiating Verve With A SellJune 18, 2025 | seekingalpha.comVerve Therapeutics (NASDAQ:VERV) Sets New 12-Month High - Here's WhyJune 18, 2025 | marketbeat.comCanaccord Genuity Group Reiterates Hold Rating for Verve Therapeutics (NASDAQ:VERV)June 18, 2025 | americanbankingnews.comVerve Therapeutics Target of Unusually High Options Trading (NASDAQ:VERV)June 18, 2025 | americanbankingnews.comThese Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and MoreJune 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockOPTN, VERV, ORIC, and TRML Company DescriptionsOptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Oric Pharmaceuticals NASDAQ:ORIC$10.00 +0.69 (+7.41%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$9.90 -0.10 (-1.04%) As of 06/23/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Tourmaline Bio NASDAQ:TRML$17.02 +0.38 (+2.28%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$16.98 -0.04 (-0.26%) As of 06/23/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Verve Therapeutics NASDAQ:VERV$11.11 +0.05 (+0.45%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$11.09 -0.02 (-0.18%) As of 06/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
